Melanie Senior
After the 2005 mergers of Yamanouchi and Fujisawa into Astellas Pharma Inc., and of Daiichi Pharmaceutical Co. Ltd. and Sankyo...
Specialty Pharma: Tapping Japan
Economic recovery, pharmaceutical consolidation, and a burgeoning private equity sector have encouraged a new cluster of Japan-focused specialty pharmas
More from Global Vision
More from In Vivo
• By
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.